beta-amyrin-palmitate and Dyslipidemias

beta-amyrin-palmitate has been researched along with Dyslipidemias* in 1 studies

Other Studies

1 other study(ies) available for beta-amyrin-palmitate and Dyslipidemias

ArticleYear
β-Amyrin acetate and β-amyrin palmitate as antidyslipidemic agents from Wrightia tomentosa leaves.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, Jun-15, Volume: 19, Issue:8-9

    The ethanolic extract and fractions of Wrightia tomentosa Roem. & Schult (Apocynaceae) leaves were tested in vivo for their antidyslipidemic activity in high fat diet (HFD) induced dyslipidemic hamsters. Activity guided isolation resulted in identification of antidyslipidemic compounds β-AA and β-AP. Compounds β-AA and β-AP decrease the levels of LDL by 36% and 44%, and increase the HDL-C/TC ratio by 49% and 28%, respectively, at a dose of 10mg/kg. In addition, the isolated compounds β-AA and β-AP showed significant HMG-CoA-reductase inhibition, which was further established by docking studies.

    Topics: Animals; Apocynaceae; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyslipidemias; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Mesocricetus; Models, Molecular; Molecular Structure; Oleanolic Acid; Plant Leaves; Plants, Medicinal

2012